IP Library › Granted Patent US 6,914,079
Granted Patent B2
US 6,914,079 · App. 10/251,819 · Granted Jul 5, 2005

Polyamine analogs that activate antizyme frameshifting

Assignee: MediQuest Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,914,079
App. No.
10/251,819
Granted
Jul 5, 2005
Kind
B2
Abstract

Novel polyamines, their synthesis and use in pharmacological, cosmetic or agricultural applications are provided. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compounds will preferably enter the cell independent of the polyamine transporter. As drugs, these compounds are used to treat any disease associated with cellular proliferation including but not limited to cancer.

Claims (8)

1. The polyamine wherein said structure is

2. The polyamine wherein said structure is

3. A polyamine represented by one of the following formulae:

4. A pharmaceutical composition useful for treating a disease or condition in which the inhibition of cell growth or proliferation is desirable, comprising a polyamine according to any one of claims 1 - 2 and 3 and a pharmaceutically acceptable excipient, diluent or vehicle.

5. A pharmaceutical composition useful for treating a disease or condition in which the inhibition of cell growth or proliferation is desirable, comprising a polyamine according to any one of claims 1 - 2 and 3 and a pharmaceutically acceptable excipient. diluent or vehicle.

6. The composition of claim 4 wherein said excipient, diluent or vehicle is pharmaceutically or cosmetically acceptable.

7. The composition of claim 4 wherein said excipient, diluent or vehicle is for topical or intra-aural administration.

8. The composition of claim 4 formulated for intravenous, subcutaneous, intramuscular, intracranial, intraperitoneal, topical, transdermal, intravaginal, intranasal, intrabronchial, intracranial, intraocular, intraaural, rectal, oral or parenteral administration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2013
From: MEDIQUEST THERAPEUTICS, INC.
To: MQT HOLDINGS, LLC
Reel/Frame 031336/0214 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2002
From: BURNS, MARK R.; GRAMINSKI, GERARD F.
To: MEDIQUEST THERAPEUTICS, INC.
Reel/Frame 013537/0358 →
Continuity (1)
Related Publication 20040058954A1 · Mar 25, 2004